Midterm results raise important questions about the benefit-to-risk ratio in balancing transcatheter aortic valve implantation (TAVI) devices and call for a re-evaluation of the evidence for TAVI in low-risk (LR) patients with aortic stenosis (AS), a new viewpoint proposes.